Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism

Nature Communications

Volumn 7, Issue , 2016, Pages

  Tang, Yuefeng ^a   Wallace, Martina ^b   Sanchez Gurmaches, Joan ^a   Hsiao, Wen Yu ^a   Li, Huawei ^a   Lee, Peter L ^a   Vernia, Santiago ^a,c   Metallo, Christian M ^b   Guertin, David A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CHREBP BETA; UNCLASSIFIED DRUG; CARRIER PROTEIN; MLXIPL PROTEIN, MOUSE; MULTIPROTEIN COMPLEX; NUCLEAR PROTEIN; PROTEIN KINASE B; PROTEIN SUBUNIT; RICTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

BIOLOGICAL UPTAKE; CELLS AND CELL COMPONENTS; DIABETES; DIET; GENE EXPRESSION; GLUCOSE; HORMONE; METABOLISM; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPOGENESIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WHITE ADIPOSE TISSUE; ADIPOCYTE; ADIPOGENESIS; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LIVER; MALE; METABOLISM; OBESITY; PATHOLOGY; PROTEIN SUBUNIT;

MUS;

ADIPOCYTES; ADIPOGENESIS; ADIPOSE TISSUE, WHITE; ANIMALS; CARRIER PROTEINS; DIET, HIGH-FAT; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GLUCOSE; INSULIN RESISTANCE; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; NUCLEAR PROTEINS; OBESITY; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 84964308646     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11365     Document Type: Article

References (55)

1. Samuel, V. T. & Shulman, G. I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Invest. 126, 12-22 (2016).
2. Titchenell, P. M., Chu, Q., Monks, B. R. & Birnbaum, M. J. Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nat. Commun. 6, 7078 (2015).
3. O-Sullivan, I. et al. FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nat. Commun. 6, 7079 (2015).
4. Perry, R. J. et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160, 745-758 (2015).
5. Herman, M. A. et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 484, 333-338 (2012).
6. Yore, M. M. et al. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell 159, 318-332 (2014).
7. Kursawe, R. et al. Decreased transcription of ChREBP-alpha/beta isoforms in abdominal subcutaneous adipose tissue of obese adolescents with prediabetes or early type 2 diabetes: associations with insulin resistance and hyperglycemia. Diabetes 62, 837-844 (2013).
8. Eissing, L. et al. De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health. Nat. Commun. 4, 1528 (2013).
9. Fuhrmann, A. et al. Molecular mechanisms underlying the effects of cyclosporin A and sirolimus on glucose and lipid metabolism in liver, skeletal muscle and adipose tissue in an in vivo rat model. Biochem. Pharmacol. 88, 216-228 (2014).
10. Turner, N. et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 56, 1638-1648 (2013).
11. Iizuka, K. Recent progress on the role of ChREBP in glucose and lipid metabolism. Endocr. J. 60, 543-555 (2013).
12. Shao, W. & Espenshade, P. J. Expanding roles for SREBP in metabolism. Cell. Metab. 16, 414-419 (2012).
13. Xu, X., So, J. S., Park, J. G. & Lee, A. H. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin. Liver Dis. 33, 301-311 (2013).
14. Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274-293 (2012).
15. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
16. Cybulski, N., Polak, P., Auwerx, J., Ruegg, M. A. & Hall, M. N. mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc. Natl Acad. Sci. USA 106, 9902-9907 (2009).
17. Kumar, A. et al. Fat cell-specific ablation of rictor in mice impairs insulinregulated fat cell and whole-body glucose and lipid metabolism. Diabetes 59, 1397-1406 (2010).
18. Mullican, S. E. et al. A novel adipose-specific gene deletion model demonstrates potential pitfalls of existing methods. Mol. Endocrinol. 27, 127-134 (2013).
19. Lee, K. Y. et al. Lessons on conditional gene targeting in mouse adipose tissue. Diabetes 62, 864-874 (2013).
20. Eguchi, J. et al. Transcriptional control of adipose lipid handling by IRF4. Cell. Metab. 13, 249-259 (2011).
21. Wang, F., Mullican, S. E., DiSpirito, J. R., Peed, L. C. & Lazar, M. A. Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARgamma. Proc. Natl Acad. Sci. USA 110, 18656-18661 (2013).
22. Hung, C. M. et al. Rictor/mTORC2 loss in the Myf5 lineage reprograms brown fat metabolism and protects mice against obesity and metabolic disease. Cell Rep. 8, 256-271 (2014).
23. Sanchez-Gurmaches, J. & Guertin, D. A. Adipocytes arise from multiple lineages that are heterogeneously and dynamically distributed. Nat. Commun. 5, 4099 (2014).
24. Abel, E. D. et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409, 729-733 (2001).
25. Witte, N. et al. The glucose sensor ChREBP links de novo lipogenesis to PPARgamma activity and adipocyte differentiation. Endocrinology 156, 4008-4019 (2015).
26. Cao, H. et al. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 134, 933-944 (2008).
27. Kien, C. L. et al. A lipidomics analysis of the relationship between dietary fatty acid composition and insulin sensitivity in young adults. Diabetes 62, 1054-1063 (2013).
28. Kien, C. L. et al. Dietary intake of palmitate and oleate has broad impact on systemic and tissue lipid profiles in humans. Am. J. Clin. Nutr. 99, 436-445 (2014).
29. Benhamed, F. et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J. Clin. Invest. 122, 2176-2194 (2012).
30. Oosterveer, M. H. et al. High fat feeding induces hepatic fatty acid elongation in mice. PLoS ONE 4, e6066 (2009).
31. Maeda, N. et al. Diet-induced insulin resistance in mice lacking adiponectin/ ACRP30. Nat. Med. 8, 731-737 (2002).
32. Kubota, N. et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 277, 25863-25866 (2002).
33. Jeffery, E. et al. Characterization of Cre recombinase models for the study of adipose tissue. Adipocyte 3, 206-211 (2014).
34. Lodhi, I. J. et al. Inhibiting adipose tissue lipogenesis reprograms thermogenesis and PPARgamma activation to decrease diet-induced obesity. Cell. Metab. 16, 189-201 (2012).
35. Cartee, G. D. & Wojtaszewski, J. F. Role of Akt substrate of 160 kDa in insulinstimulated and contraction-stimulated glucose transport. Appl. Physiol. Nutr. Metab. 32, 557-566 (2007).
36. Blot, V. & McGraw, T. E. Use of quantitative immunofluorescence microscopy to study intracellular trafficking: studies of the GLUT4 glucose transporter. Methods Mol. Biol. 457, 347-366 (2008).
37. Masui, K. et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell. Metab. 18, 726-739 (2013).
38. Otero, Y. F., Stafford, J. M. & McGuinness, O. P. Pathway-selective insulin resistance and metabolic disease: the importance of nutrient flux. J. Biol. Chem. 289, 20462-20469 (2014).
39. Czech, M. P., Tencerova, M., Pedersen, D. J. & Aouadi, M. Insulin signalling mechanisms for triacylglycerol storage. Diabetologia 56, 949-964 (2013).
40. Tan, S. X. et al. Selective insulin resistance in adipocytes. J. Biol. Chem. 290, 11337-11348 (2015).
41. Gonzalez, E., Flier, E., Molle, D., Accili, D. & McGraw, T. E. Hyperinsulinemia leads to uncoupled insulin regulation of the GLUT4 glucose transporter and the FoxO1 transcription factor. Proc. Natl Acad. Sci. USA 108, 10162-10167 (2011).
42. Matsuzaka, T. et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat. Med. 13, 1193-1202 (2007).
43. Guillou, H., Zadravec, D., Martin, P. G. & Jacobsson, A. The key roles of elongases and desaturases in mammalian fatty acid metabolism: insights from transgenic mice. Prog. Lipid Res. 49, 186-199 (2010).
44. Zadravec, D. et al. Ablation of the very-long-chain fatty acid elongase ELOVL3 in mice leads to constrained lipid storage and resistance to diet-induced obesity. FASEB J. 24, 4366-4377 (2010).
45. Perry, R. J., Samuel, V. T., Petersen, K. F. & Shulman, G. I. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84-91 (2014).
46. Karpe, F., Dickmann, J. R. & Frayn, K. N. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 60, 2441-2449 (2011).
47. Davidson, J. et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting, Barcelona, Spain, 19 February 2003. Transplantation 75, SS3-24 (2003).
48. Wilkinson, A. et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin. Transplant. 19, 291-298 (2005).
49. Badiou, S., Cristol, J. P. & Mourad, G. Dyslipidemia following kidney transplantation: diagnosis and treatment. Curr. Diabetes Rep. 9, 305-311 (2009).
50. Ma, K. L. et al. Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia. Transplantation 84, 1029-1036 (2007).
51. Chow, K. M. & Li, P. K. Review article: new-onset diabetes after transplantation. Nephrology 13, 737-744 (2008).
52. Lamming, D. W. et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335, 1638-1643 (2012).
53. Shiota, C., Woo, J. T., Lindner, J., Shelton, K. D. & Magnuson, M. A. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 11, 583-589 (2006).
54. Kim, H. J. et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53, 1060-1067 (2004).
55. Lewis, C. A. et al. Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. Mol. Cell 55, 253-263 (2014).